Drug Database
Back to search

Japan· JP-1319722Q1228

オフロキサシン

A ofloxacin product containing オフロキサシン, registered in Japan by 日新製薬（山形）, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.

On Japan’s NHI price listATC J01MA01

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedオフロキサシンATCJ01MA01REGISTER NO.JP-1319722Q1228PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about オフロキサシンAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ofloxacin is registered in 10 of 19 countries.

Countries holding a registration under ATC J01MA01 (ofloxacin), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 6 of them publish a price we can compare per daily dose
Search ofloxacin products by name

Ofloxacin · ATC J01MA01

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Germany
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
オフロキサシン
Manufacturer
日新製薬（山形）
Country
Japan (JP)
ATC code
J01MA01
ATC class
Ofloxacin
Defined daily dose
0.4 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

596 interactions on record for ofloxacin.

Graded by severity as the source publishes them — 86 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ofloxacin against other medicinesHow interaction checks work

Ofloxacin · interactions on record

596 records

  • 86 severe
  • 216 moderate
  • 51 minor
  • 170 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PrednisoloneA07EA01severe

73 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ofloxacin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ofloxacin products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Floxal, Floxal Edo
  • Belgium · Trafloxal, Trafloxal Edo
  • Bulgaria · Медофлоксин, Офлоксацин Дра
  • Cyprus · Cilox, Medofloxine
  • Czechia · Floxal, Ofloxacin Unimed Pharma
  • Germany · Floxal, Floxal Edo
  • Estonia · Medofloxine, Ofloxin
  • Spain · Exocin, Oflovir
  • Finland · Exocin
  • France · Exocine, Monoflocet
  • United Kingdom (Northern Ireland) · Exocin, Ofloxacin Bristol Laboratories
  • Greece · Exocin, Oxatrex
  • Croatia · Uniflox
  • Hungary · Floxal, Grenis-Oflo
  • Ireland · Exocin
  • Italy · Dunaflot, Exocin
  • Lithuania · Ofloxin, Uniflox
  • Luxembourg · Ofloxa-Vision Kombi-Packung, Visioflox
  • Latvia · Ofloxin, Uniflox
  • Malta · Uniflox Unimed Pharma
  • Netherlands · Ofloxacine 200 Pch, Ofloxacine 400 Pch
  • Poland · Floxal, Oflodinex
  • Portugal · Audret, Bioquil
  • Romania · Floxal, Ofloxacină Laropharm
  • Sweden · Ofloxacin Mibe
  • Slovakia · Medofloxine, Ofloxin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/72f76d02-2056-4cbb-b04d-13a3b067c19e
GET /v1/drugs/72f76d02-2056-4cbb-b04d-13a3b067c19e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "０．３％１ｍＬ",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "1319722Q1228",
  "category": "外用薬",
  "price_yen": 34.6,
  "generic_name": "オフロキサシン",
  "product_name_jp": null,
  "therapeutic_class": "1319",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about ofloxacin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console